Raltegravir

Raltegravir has been studied in 5 papers since 2016: 4 trials in people, 1 in cells. The newest paper, Jul 20, 2021: “Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial”.

Intervention

5 papers study it4 more mention it6 findingsUpdated

PubChemChEBI

See all 9 papers on raltegravir

At a glance

The findings reach people, from one lab or study. 3 independent labs in 1 country; 17 trials, none about aging, 4 with no results posted.

“There were no significant differences in the ART effect on epigenetic ageing between treatment regimens.”
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trialThe lancet. HIV2021doi:10.1016/s2352-3018(21)00006-0

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 1 country
  • 17 trials, none about aging, 4 with no results posted
  • Funders: Gilead Sciences and 6 more
  • 2 of 6 findings with company ties
  • Human trial4
  • Cells1

Studies in people

3 studies gave raltegravir to people and measured what changed.

What changedDesignPeopleSource

down: Decreases activated T lymphocytesCD4+CD38+HLA-DR+ -0.3 vs 0.48 (P = 0.033); CD8+CD38+HLA-DR+ -1.6 vs 1.3 (P = 0.02)

down: Decreases senescent T lymphocytesCD4+CD28-CD57+ -0.3 vs 0.26 (P = 0.04); CD8+CD28-CD57+ -6.1 vs 3.8 (P = 0.002)

up: Increases CD4/CD8 ratiomedian +0.35 vs +0.03 in other arms

Randomized trial48 weeks48 peopleHIV medicine, Jul 20, 2021

no change: Has no effect on epigenetic age

Randomized trial2 years168 peoplePatient cohortsThe lancet. HIV, Apr 1, 2021

down: Decreases CD38+ CD8+ T cells

up: Increases CD28- CD57+ T cells

Randomized trial24 weeks42 people≥40 yearsMidlife adults; switch from protease inhibitor to raltegravirPloS one, Sep 17, 2020

What did studies of raltegravir find?

6

Studies of raltegravir measured 6 outcomes, among them CD4/CD8 ratio, Senescent T lymphocytes and Activated T lymphocytes.

CD4/CD8 ratio

upin humans1

1 study
  1. Raltegravir increases CD4/CD8 ratio in humans (median +0.35 vs +0.03 in other arms).

    “the median CD4/CD8 ratio increased by 0.35 in patients in the raltegravir group vs. 0.03 in the other arms (P = 0.002)”

    Human trial48 weeks

    Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial

    HIV medicine

More on CD4/CD8 ratio

Senescent T lymphocytes

downin humans1

1 study
  1. Raltegravir decreases senescent T lymphocytes in humans (CD4+CD28-CD57+ -0.3 vs 0.26 (P = 0.04); CD8+CD28-CD57+ -6.1 vs 3.8 (P = 0.002)).

    “switching to a regimen with raltegravir significantly decreased activated and senescent T-lymphocyte subpopulations”

    Human trial48 weeks

    Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial

    HIV medicine

Activated T lymphocytes

downin humans1

1 study
  1. Raltegravir decreases activated T lymphocytes in humans (CD4+CD38+HLA-DR+ -0.3 vs 0.48 (P = 0.033); CD8+CD38+HLA-DR+ -1.6 vs 1.3 (P = 0.02)).

    “patients who switched to raltegravir showed a higher decrease in all activated”

    Human trial48 weeks

    Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial

    HIV medicine

Epigenetic age

no changein humans1

1 study
  1. Raltegravir showed no clear effect on epigenetic age in humans.

    “There were no significant differences in the ART effect on epigenetic ageing between treatment regimens.”

    Human trialcompared with tenofovir disoproxil fumarate/emtricitabine, both combined with ritonavir-boosted darunavirwhole blood2 yearsn = 168

    Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial

    The lancet. HIV

More on Epigenetic age

CD28- CD57+ T cells

upin humans1

1 study
  1. Raltegravir increases CD28- CD57+ T cells in humans (switch from protease inhibitor to raltegravir).

    “an increase in the frequency of CD28-CD57+ in both CD4 and CD8 T-cell compartments were noticed in the Raltegravir-switched group”

    Human trialswitch from protease inhibitor to raltegravirCD4 and CD8 T cells

    A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV

    PloS one

More on CD28- CD57+ T cells

CD38+ CD8+ T cells

downin humans1

1 study
  1. Raltegravir decreases CD38+ CD8+ T cells in humans (switch from protease inhibitor to raltegravir).

    “Only a modest decrease in the frequency of CD38+ CD8 T cells”

    Human trialswitch from protease inhibitor to raltegravir

    A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV

    PloS one

More on CD38+ CD8+ T cells

Trial sponsors

Latest